Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →Gland Pharma Limited — Q1 FY25
Gland Pharma reported consolidated revenue of INR 14,070 million (+16% YoY), driven by 14% growth in the base business and Cenexi contribution.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Gland Pharma reported consolidated revenue of INR 14,070 million (+16% YoY), driven by 14% growth in the base business and Cenexi contribution. Base business EBITDA margin held at 29%, while consolidated margin fell to 19% due to Cenexi's negative EBITDA. U.S. revenues grew 27% YoY on volume and new launches, but sequentially declined 13% due to milestone income normalization and a low-margin GPO contract. Cenexi revenue was EUR 43 million with negative EBITDA of EUR 3 million; management expects positive EBITDA by Q4 FY25. Biologics CDMO discussions are advancing, including a potential strategic collaboration. Risks include Cenexi's turnaround timeline, U.S. pricing pressure, and execution on biologics investments.
ग्लैंड फार्मा की कुल आय 1,407 करोड़ रुपये रही, जो पिछले साल से 16% ज्यादा है। इसकी वजह मुख्य कारोबार में 14% बढ़ोतरी और सीनेक्सी कंपनी का योगदान है। मुख्य कारोबार का मुनाफा 29% रहा, लेकिन सीनेक्सी के घाटे की वजह से कुल मुनाफा घटकर 19% हो गया। अमेरिका में बिक्री 27% बढ़ी, लेकिन पिछली तिमाही से 13% कम हुई। सीनेक्सी ने 43 मिलियन यूरो की बिक्री पर 3 मिलियन यूरो का घाटा दिया, लेकिन कंपनी को उम्मीद है कि मार्च 2025 तक यह मुनाफे में आ जाएगी। बायोलॉजिक्स दवाओं के लिए नई साझेदारी की बात चल रही है। जोखिमों में सीनेक्सी का सुधार, अमेरिका में कीमतों का दबाव और नए निवेशों पर अमल शामिल है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Cenexi turnaround delay
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
U.S. Revenue Growth (YoY)
27%
+27% YoY
U.S. market grew 27% YoY driven by volume share of existing products and new launches.
Base Business EBITDA Margin
29%
-100bps YoY
Base business EBITDA margin was 29% vs 30% in Q1 FY24, impacted by product mix.
Cenexi Revenue
EUR 43M
N/A (not comparable)
Cenexi contributed EUR 43 million in revenue; negative EBITDA of EUR 3 million.
ANDAs Filed/Approved
8 filed, 7 approved
N/A
Filed 8 ANDAs and received 7 approvals during the quarter.
What Changed vs Last Quarter
NEW
Base business EBITDA margin 30-33% for FY25
Management guided base business EBITDA margin in the range of 30-33% for the full year.
NEW
Cenexi positive EBITDA by Q4 FY25
Cenexi is expected to achieve positive EBITDA by the fourth quarter of this fiscal year.
NEW
Cenexi revenue to exceed EUR 200 million in FY26
Cenexi expects revenue to exceed EUR 200 million in the next fiscal year, driving positive EBITDA.
UPDATED
Base business mid-teens revenue growth for FY25
Management expects base business (ex-Cenexi) to grow in mid-teens for the full fiscal year.
DROPPED
Cenexi to reach high-teen EBITDA margins in 1-2 years
Cenexi targets high-teen EBITDA margins within 1-2 years through operational fixes, tech transfers, and capacity expansion.
DROPPED
Cenexi quarterly revenue to ramp to EUR 50M in ~3 quarters
Cenexi's quarterly revenue is expected to gradually increase from EUR 40M to EUR 50M in about three quarters.
NEW RISK
Biologics collaboration execution risk
Discussions for a strategic biologics collaboration are early-stage; may require significant investment with uncertain timeline.
NEW RISK
Fosun stake sale overhang
Fosun sold a large stake in the quarter; management has no visibility on future share sales, which could impact sentiment.
RISK GONE
Slow progress in biologics and China
Biologics CDMO and China market progress have been slower than anticipated, with no near-term material contribution expected.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q3 FY24, Q4 FY24
Cenexi's operational issues and capacity constraints may delay profitability, with management acknowledging a few quarters delay.
Mentioned in Q1 FY24, Q2 FY24
Cenexi's annual summer shutdown (4 weeks in France, 3 in Belgium) will continue to cause revenue loss and negative EBITDA in Q2 each year.
Mentioned in Q2 FY24, Q3 FY24
New programs in tech transfer and approval stages are expected to add EUR 30-40 million to Cenexi's annual revenue in the medium term.
Mentioned in Q1 FY24, Q2 FY24
Management declined to provide a timeline for Cenexi reaching 13-15% EBITDA margins, citing early stage of integration.
Mentioned in Q1 FY24, Q2 FY24
Management expects steady quarter-on-quarter growth in the base business, driven by new launches and volume expansion.
Fast read
Guidance and risk preview
Management expects base business (ex-Cenexi) to grow in mid-teens for the full fiscal year.
Cenexi is still a few quarters away from a complete turnaround; Q2 will be impacted by extended summer shutdown.
View Risks →